Non alcoholic fatty liver disease and dark chocolate

Effect of dark chocolate on serum levels of liver enzymes, inflammation and oxidative stress status in patients with non alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201303264545N2

Enrollment

Registered

2014-12-25

Start date

2013-10-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver. Non alcoholic fatty liver disease

Interventions

Intervention 1: Intervention group: daily consumption of 30 grams dark chocolate 83% (made by Iran Shirin Asal Company) for 3 months. Intervention 2: Control group: without consuming dark chocolate f

Treatment - Drugs

Intervention group: daily consumption of 30 grams dark chocolate 83% (made by Iran Shirin Asal Company) for 3 months

Control group: without consuming dark chocolate for 3 months

Eligibility

Sex/Gender

All

Age

19 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 19-59 years old patient with non alcoholic fatty liver disease Exclusion criteria: Patients who have diabetes, cardiovascular, kidney and other hepatic diseases; Pregnant or lactating women; Smoking; Alcohol consumption; Use of dietary supplements.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nuclear factor-kappa B. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Aspartate aminotransferase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;High-sensitivity C-reactive Protein. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Triglyciride. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Photometric.;Malondialdehyde. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Total antioxidant capacity. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Alanine transaminase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;VLDL. Timepoint: Before intervention and 3 month after intervention. Method of measurement: TG/5.;LDL-C. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Fridewald method.;Fasting blood sugar. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;HDL-C. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Enzymatic.	—

Measure

Time frame

Nuclear factor-kappa B. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Aspartate aminotransferase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;High-sensitivity C-reactive Protein. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Triglyciride. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Photometric.;Malondialdehyde. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Total antioxidant capacity. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;Alanine transaminase. Timepoint: Before intervention and 3 months after intervention. Method of measurement: ELISA.;VLDL. Timepoint: Before intervention and 3 month after intervention. Method of measurement: TG/5.;LDL-C. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Fridewald method.;Fasting blood sugar. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Photometric.;HDL-C. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Enzymatic.

—

Secondary

Measure	Time frame
Body weight. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Digital scale.;Blood pressure. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Blood pressure monitor.;Body mass index. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Body weight in kilograms divided by height squared in meters.;Waist circumference. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Meter.;Hip circumefrence. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Meter.;Waist Hip Ratio. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Waist circumference to hip Circumference ratio.	—

Measure

Time frame

Body weight. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Digital scale.;Blood pressure. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Blood pressure monitor.;Body mass index. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Body weight in kilograms divided by height squared in meters.;Waist circumference. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Meter.;Hip circumefrence. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Meter.;Waist Hip Ratio. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Waist circumference to hip Circumference ratio.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz farsi

Research Institute for Infectious Diseases of Digestive System, Ahvaz Jundi Shapur University of Med

farnaz.farsi@yahoo.com+98 61 1292 1839

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026